SK287761B6 - Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor - Google Patents

Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor Download PDF

Info

Publication number
SK287761B6
SK287761B6 SK1556-2002A SK15562002A SK287761B6 SK 287761 B6 SK287761 B6 SK 287761B6 SK 15562002 A SK15562002 A SK 15562002A SK 287761 B6 SK287761 B6 SK 287761B6
Authority
SK
Slovakia
Prior art keywords
inhibitor
medicament
use according
body weight
treatment
Prior art date
Application number
SK1556-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK15562002A3 (sk
Inventor
Yolande Chvatchko
Ziad Mallat
Alain Tedgui
Original Assignee
Applied Research Systems Ars Holding N. V.
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N. V., Institut National De La Sante Et De La Recherche Medicale filed Critical Applied Research Systems Ars Holding N. V.
Publication of SK15562002A3 publication Critical patent/SK15562002A3/sk
Publication of SK287761B6 publication Critical patent/SK287761B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SK1556-2002A 2000-05-05 2001-04-30 Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor SK287761B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (fr) 2000-05-05 2001-04-30 Utilisation d'inhibiteurs il-18 pour le traitement et/ou la prevention de l'atherosclerose

Publications (2)

Publication Number Publication Date
SK15562002A3 SK15562002A3 (sk) 2003-05-02
SK287761B6 true SK287761B6 (en) 2011-09-05

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1556-2002A SK287761B6 (en) 2000-05-05 2001-04-30 Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor

Country Status (33)

Country Link
US (1) US20040076628A1 (fr)
EP (1) EP1278540B1 (fr)
JP (1) JP5122053B2 (fr)
KR (2) KR100798545B1 (fr)
CN (2) CN1250286C (fr)
AR (1) AR035640A1 (fr)
AT (1) ATE395075T1 (fr)
AU (2) AU2001267390B2 (fr)
BG (1) BG65881B1 (fr)
BR (1) BRPI0110506B8 (fr)
CA (1) CA2407895C (fr)
CY (1) CY1110385T1 (fr)
CZ (1) CZ300792B6 (fr)
DE (1) DE60134009D1 (fr)
DK (1) DK1278540T3 (fr)
EA (2) EA005410B1 (fr)
EE (1) EE05056B1 (fr)
ES (1) ES2305082T3 (fr)
HK (2) HK1055681A1 (fr)
HR (1) HRP20020828A2 (fr)
HU (1) HU229375B1 (fr)
IL (2) IL152567A0 (fr)
ME (1) ME00554B (fr)
MX (1) MXPA02010895A (fr)
NO (1) NO329821B1 (fr)
PL (1) PL209371B1 (fr)
PT (1) PT1278540E (fr)
RS (1) RS50926B (fr)
SI (1) SI1278540T1 (fr)
SK (1) SK287761B6 (fr)
UA (2) UA78492C2 (fr)
WO (1) WO2001085201A2 (fr)
ZA (1) ZA200208228B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EE05534B1 (et) * 2001-01-29 2012-04-16 Applied Research Systems Ars Holding N.V. IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
BR0210007A (pt) * 2001-05-25 2004-08-10 Ares Trading Sa Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US9592267B2 (en) * 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
CN100429315C (zh) * 2003-03-11 2008-10-29 雪兰诺实验室有限公司 含有mcmv ie2启动子的表达载体
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Il−18結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CA2563408C (fr) * 2004-04-15 2015-08-25 Athera Biotechnologies Ab Utilisation de l'annexine v pour la prevention de l'atherothrombose et de la rupture de la plaque
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术(上海)有限公司 白介素-22的医药用途
CA2609060C (fr) 2005-06-03 2014-07-15 Urs Weber Production d'une proteine de liaison il-18 recombinee
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Il−18結合タンパク質の精製のための方法
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
MX2016002719A (es) 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
EP3265807A1 (fr) 2015-03-05 2018-01-10 AB2 Bio SA Protéine de liaison à l'il-18 (il-18 bp) et anticorps dans des maladies inflammatoires
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Il-18拮抗劑用於治療和/或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (fr) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide artificiel capable de neutraliser l'activite biologique de l'interleukine-18
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
EP1110969A4 (fr) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
CN1841066B (zh) 2012-08-29
CN1250286C (zh) 2006-04-12
KR100798545B1 (ko) 2008-01-28
SK15562002A3 (sk) 2003-05-02
EA200401183A1 (ru) 2004-12-30
EA007014B1 (ru) 2006-06-30
CN1841066A (zh) 2006-10-04
CZ20023644A3 (cs) 2003-03-12
ME00554B (me) 2012-03-20
CN1434722A (zh) 2003-08-06
BG107218A (bg) 2003-06-30
MXPA02010895A (es) 2003-03-27
YU82602A (sh) 2006-01-16
AU2001267390B2 (en) 2005-09-22
DK1278540T3 (da) 2008-07-21
BRPI0110506B1 (pt) 2015-05-19
UA78492C2 (en) 2007-04-10
HK1094909A1 (en) 2007-04-13
US20040076628A1 (en) 2004-04-22
HK1055681A1 (en) 2004-01-21
IL152567A0 (en) 2003-05-29
HUP0301991A3 (en) 2006-11-28
ZA200208228B (en) 2005-07-27
DE60134009D1 (de) 2008-06-26
AU6739001A (en) 2001-11-20
KR20070073989A (ko) 2007-07-10
WO2001085201A2 (fr) 2001-11-15
BRPI0110506B8 (pt) 2021-05-25
EE200200620A (et) 2004-06-15
PT1278540E (pt) 2008-07-03
BG65881B1 (bg) 2010-04-30
HUP0301991A2 (hu) 2003-09-29
AR035640A1 (es) 2004-06-23
EP1278540A2 (fr) 2003-01-29
NO20025307D0 (no) 2002-11-05
ATE395075T1 (de) 2008-05-15
JP2003532685A (ja) 2003-11-05
CA2407895A1 (fr) 2001-11-15
WO2001085201A3 (fr) 2002-05-10
NO329821B1 (no) 2010-12-27
RS50926B (sr) 2010-08-31
EP1278540B1 (fr) 2008-05-14
CZ300792B6 (cs) 2009-08-12
CY1110385T1 (el) 2015-04-29
EE05056B1 (et) 2008-08-15
EA200201175A1 (ru) 2003-04-24
NO20025307L (no) 2002-12-18
IL152567A (en) 2010-12-30
PL209371B1 (pl) 2011-08-31
HRP20020828A2 (en) 2004-12-31
SI1278540T1 (sl) 2008-10-31
BR0110506A (pt) 2003-04-01
ES2305082T3 (es) 2008-11-01
MEP64008A (en) 2011-12-20
EA005410B1 (ru) 2005-02-24
PL365697A1 (en) 2005-01-10
CA2407895C (fr) 2012-12-18
JP5122053B2 (ja) 2013-01-16
UA87658C2 (uk) 2009-08-10
KR20030016254A (ko) 2003-02-26
HU229375B1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
SK287761B6 (en) Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor
AU2001267390A1 (en) Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
EA009125B1 (ru) Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции
JP2004517918A (ja) Il−17アンタゴニストを使用する慢性関節リューマチの治療法
HRP20040758A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
US20110177065A1 (en) Methods of treating/preventing inflammation using combination of il-1 antagonist and il-18 binding protein
BG66483B1 (bg) Използване на инхибитори на интерлевкин -18 за лечение и/или профилактика на сърдечни заболявания
AU2005211606B2 (en) Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N. V., CURACAO, AN; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), PARIS CEDEX, FR

Effective date: 20120423

Owner name: LABORATOIRES SERONO SA, COINSINS, VAUD, CH

Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N. V., CURACAO, AN; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), PARIS CEDEX, FR

Effective date: 20120423

TC4A Change of owner's name

Owner name: MERCK SERONO SA, COINSINS, VAUD, CH

Effective date: 20120709

MK4A Patent expired

Expiry date: 20210430